AP2327A - Quinoline derivatives for the treatment of latent tuberculosis. - Google Patents

Quinoline derivatives for the treatment of latent tuberculosis.

Info

Publication number
AP2327A
AP2327A AP2007004054A AP2007004054A AP2327A AP 2327 A AP2327 A AP 2327A AP 2007004054 A AP2007004054 A AP 2007004054A AP 2007004054 A AP2007004054 A AP 2007004054A AP 2327 A AP2327 A AP 2327A
Authority
AP
ARIPO
Prior art keywords
treatment
quinoline derivatives
latent tuberculosis
tuberculosis
latent
Prior art date
Application number
AP2007004054A
Other languages
English (en)
Other versions
AP2007004054A0 (en
Inventor
Koenraad Jozef Lodewijk Marcel Andries
Anil Koul
Original Assignee
Janssen Pharmaceutica Nl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35717702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2327(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nl filed Critical Janssen Pharmaceutica Nl
Publication of AP2007004054A0 publication Critical patent/AP2007004054A0/xx
Application granted granted Critical
Publication of AP2327A publication Critical patent/AP2327A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AP2007004054A 2004-12-24 2005-12-08 Quinoline derivatives for the treatment of latent tuberculosis. AP2327A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04078529 2004-12-24
EP05105008 2005-06-08
PCT/EP2005/056594 WO2006067048A1 (fr) 2004-12-24 2005-12-08 Derives de quinoline destines au traitement de la tuberculose latente

Publications (2)

Publication Number Publication Date
AP2007004054A0 AP2007004054A0 (en) 2007-06-30
AP2327A true AP2327A (en) 2011-11-25

Family

ID=35717702

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2007004054A AP2327A (en) 2004-12-24 2005-12-08 Quinoline derivatives for the treatment of latent tuberculosis.

Country Status (31)

Country Link
US (1) US20060142279A1 (fr)
EP (1) EP1830850B1 (fr)
CN (1) CN103142595B (fr)
AP (1) AP2327A (fr)
AR (1) AR051790A1 (fr)
AT (1) ATE501721T1 (fr)
AU (1) AU2005242138B2 (fr)
BR (1) BRPI0506400B8 (fr)
CA (1) CA2529265C (fr)
CR (1) CR9267A (fr)
CY (1) CY1112247T1 (fr)
DE (1) DE602005026984D1 (fr)
DK (1) DK1830850T3 (fr)
EE (1) EE05394B1 (fr)
HK (1) HK1186125A1 (fr)
HR (1) HRP20110392T1 (fr)
IL (1) IL184123A (fr)
LV (1) LV13469B (fr)
ME (1) ME01207B (fr)
MY (1) MY145845A (fr)
NI (1) NI200700146A (fr)
NO (1) NO340376B1 (fr)
NZ (1) NZ555460A (fr)
PA (1) PA8654801A1 (fr)
PL (1) PL1830850T3 (fr)
PT (1) PT1830850E (fr)
RS (1) RS51730B (fr)
SI (1) SI1830850T1 (fr)
TR (1) TR200504892A1 (fr)
TW (1) TWI404535B (fr)
WO (1) WO2006067048A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2421A (en) * 2002-07-25 2012-06-08 Janssen Pharmaceutica Nl Quinoline derivatives and their use as mycobacterial inhibitors.
MY173664A (en) * 2005-06-28 2020-02-14 Janssen Pharmaceutica Nv Quinoline derivatives as antibacterial agents
JO2752B1 (en) * 2005-06-28 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO3270B1 (ar) * 2005-06-28 2018-09-16 Janssen Pharmaceutica Nv مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
JO3271B1 (ar) 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
JO2725B1 (en) * 2006-12-06 2013-09-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2970B1 (en) * 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
WO2009091324A1 (fr) * 2008-01-14 2009-07-23 Jyoti Chattopadhyaya Dérivés de quinoléine, de naphtalène, de quinoléine ou de naphtalène contraint au niveau conformation en tant qu'agents antimycobactériens
RU2404971C2 (ru) * 2008-12-02 2010-11-27 ЗАО "Фарм-Синтез" Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе
US8741917B2 (en) 2009-01-15 2014-06-03 Rutgers, The State University Of New Jersey Benzo [C] phenanthridines as antimicrobial agents
US20120059026A1 (en) 2009-04-30 2012-03-08 University Of Medicine And Dentistry Of New Jersey Antimicrobial agents
WO2011156626A1 (fr) 2010-06-09 2011-12-15 Rutgers, The State University Of New Jersey Agents antimicrobiens
CA2803890A1 (fr) 2010-06-25 2011-12-29 Rutgers, The State University Of New Jersey Agents antimicrobiens
WO2013106756A2 (fr) 2012-01-13 2013-07-18 Rutgers, The State University Of New Jersey Agents antimicrobiens
US9475783B2 (en) 2012-03-21 2016-10-25 Rutgers, The State University Of New Jersey Antimicrobial agents
PL2841426T3 (pl) 2012-04-27 2017-03-31 Janssen Pharmaceutica N.V. Przeciwbakteryjne pochodne chinoliny
AU2013254674B2 (en) 2012-04-27 2017-02-02 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
US9458150B2 (en) 2013-11-08 2016-10-04 Rutgers, The State University Of New Jersey Antimicrobial agents
RS64308B1 (sr) 2015-01-27 2023-07-31 Janssen Pharmaceutica Nv Disperzibilni sastavi
EP3419967A4 (fr) 2016-02-25 2019-10-16 Taxis Pharmaceuticals, Inc. Procédés et intermédiaires de synthèse
CA3226824A1 (fr) * 2016-03-07 2017-09-14 The Global Alliance For Tb Drug Development, Inc. Composes antibacteriens et utilisations de ceux-ci
RU2629369C1 (ru) * 2016-10-05 2017-08-29 Федеральное Государственное Унитарное Предприятие "Государственный Ордена Трудового Красного Знамени Научно-Исследовательский Институт Химических Реактивов И Особо Чистых Химических Веществ" Четвертичные аммонийные производные 2-аминотиофен-3-карбоксилатов, обладающие противотуберкулезной активностью
CA3058183A1 (fr) 2017-03-30 2018-10-04 Taxis Pharmaceuticals, Inc. Procedes de synthese et intermediaires de synthese
CN115252548A (zh) 2017-07-14 2022-11-01 詹森药业有限公司 长效配制品
RU2661151C1 (ru) * 2017-12-14 2018-07-12 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Селективные ингибиторы глицеральдегид-3-фосфатдегидрогеназы микобактерий
US20220062319A1 (en) 2019-01-09 2022-03-03 Janssen Pharmaceutica Nv Combination in the treatment of nontuberculous mycobacterial diseases
CN115867259A (zh) 2020-07-09 2023-03-28 詹森药业有限公司 长效配制品
CN115776882A (zh) 2020-07-09 2023-03-10 詹森药业有限公司 长效配制品
EP4243800A1 (fr) 2020-11-12 2023-09-20 JANSSEN Pharmaceutica NV Association de bédaquiline, d'éthambutol et d'un macrolide dans le traitement de maladies mycobactériennes non tuberculeuses
WO2023232838A1 (fr) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bédaquiline destinée à être utilisée dans le traitement de la lèpre
WO2024068699A1 (fr) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Formulations à action prolongée
WO2024068693A1 (fr) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Formulations à action prolongée

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003072553A1 (fr) * 2002-02-25 2003-09-04 Pharmacia & Upjohn Company N-aryl-2-oxazolidinone-5-carboxamides et leurs derives et utilisation de ces composes comme antibacteriens
WO2004011436A1 (fr) * 2002-07-25 2004-02-05 Janssen Pharmaceutica N.V. Derives de quinoleine et leur utilisation en tant qu'inhibiteurs mycobacteriens

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003072553A1 (fr) * 2002-02-25 2003-09-04 Pharmacia & Upjohn Company N-aryl-2-oxazolidinone-5-carboxamides et leurs derives et utilisation de ces composes comme antibacteriens
WO2004011436A1 (fr) * 2002-07-25 2004-02-05 Janssen Pharmaceutica N.V. Derives de quinoleine et leur utilisation en tant qu'inhibiteurs mycobacteriens

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NPL NUERMBERGER ERIC ET AL: "Latent tuberculosis infection." SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE. JUN 2004, vol. 25, no. 3, June 2004 (2004-06), pages 317-336, XP009061348 ISSN: 1069-3424 *

Also Published As

Publication number Publication date
BRPI0506400A8 (pt) 2017-09-12
EE05394B1 (et) 2011-04-15
AR051790A1 (es) 2007-02-07
EP1830850B1 (fr) 2011-03-16
PL1830850T3 (pl) 2011-07-29
DE602005026984D1 (de) 2011-04-28
NZ555460A (en) 2008-11-28
NO340376B1 (no) 2017-04-10
EP1830850A1 (fr) 2007-09-12
SI1830850T1 (sl) 2011-07-29
CR9267A (es) 2008-09-09
AP2007004054A0 (en) 2007-06-30
WO2006067048A1 (fr) 2006-06-29
CA2529265C (fr) 2014-02-11
LV13469B (en) 2007-01-20
HRP20110392T1 (hr) 2011-06-30
AU2005242138B2 (en) 2011-05-26
CN103142595B (zh) 2015-05-06
AU2005242138A1 (en) 2006-07-13
TW200637551A (en) 2006-11-01
US20060142279A1 (en) 2006-06-29
PA8654801A1 (es) 2006-08-03
ATE501721T1 (de) 2011-04-15
IL184123A0 (en) 2008-12-29
TWI404535B (zh) 2013-08-11
DK1830850T3 (da) 2011-06-14
BRPI0506400B8 (pt) 2021-05-25
BRPI0506400B1 (pt) 2021-04-06
NI200700146A (es) 2019-05-10
NO20073823L (no) 2007-07-23
RS51730B (en) 2011-10-31
TR200504892A1 (tr) 2010-04-21
ME01207B (fr) 2013-03-20
CY1112247T1 (el) 2015-12-09
CN103142595A (zh) 2013-06-12
BRPI0506400A (pt) 2006-08-29
EE200500033A (et) 2006-08-15
PT1830850E (pt) 2011-05-31
IL184123A (en) 2011-10-31
CA2529265A1 (fr) 2006-06-24
MY145845A (en) 2012-04-30
HK1186125A1 (en) 2014-03-07

Similar Documents

Publication Publication Date Title
AP2327A (en) Quinoline derivatives for the treatment of latent tuberculosis.
AP2378A (en) Sulfonamide derivatives for the treatment of diseases.
AP2359A (en) Sulfonamide derivatives for the treatment of diseases.
AP2321A (en) Quinoline derivatives for use as mycobactrial inhibitor.
AP2037A (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
AP2507A (en) Quinoline derivatives and use thereof as mycobacterial inhibitors.
GB0419072D0 (en) Phthalazinone derivatives
ZA200610592B (en) Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase
IL181408A0 (en) 4-heteroarylmethyl substituted phthalazinone derivatives
IL177232A0 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
EP1750513A4 (fr) Utilisation de ligands gpcr54 pour le traitement de l'infertilite
HK1104235A1 (en) S-mirtazapine for the treatment of hot flush
EP1750698A4 (fr) Dérivés de 5-anilino-4-hétéroarylpyrazole utiles pour le traitement du diabete
ZA200705160B (en) Quinoline derivatives for the treatment of latent tuberculosis
ZA200800921B (en) Pyrazolone derivatives for the treatment of tuberculosis
ZA200608015B (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
AP2005003270A0 (en) Composition for the treatment of humans.
GB0412299D0 (en) Method for the synthesis of halogenated heterocycles
GB0224232D0 (en) Use of fluoroquinolone antibodies for the treatment of anthrax
PL372016A1 (pl) Sposób wytwarzania pochodnych N-fenylo-2-pirymidynoamin
GB0408297D0 (en) Indole derivatives for the treatment of diseases
HK1096379A1 (en) Sulfonamide derivatives for the treatment of diseases